Sanofi API Unit Expects $1bn Sales By 2022

New API Company Will Cut European Reliance On Asian Raw Materials

Sanofi has announced plans to create the world’s second-largest API manufacturer to help ease European drugmakers’ dependence on supplies of raw materials from China and India.

Sanofi_Israel
Sanofi says its plan to create a new API manufacturer will ease dependence on Asian supplies of raw materials • Source: Shutterstock

Sanofi has announced plans to launch a “powerhouse” active pharmaceutical ingredient manufacturing company aimed at helping avert shortages of key drug raw materials in Europe and elsewhere and balance the pharmaceutical industry’s heavy reliance on essential molecules sourced from Asia. 

The Paris-based drugmaker said the plans to set up what it says will be the world’s second-largest API manufacturing company have been in the works for a while and are...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

‘Obsessive’ Teva Aims For $800m Biosimilar Sales By 2027

 
• By 

Teva says it is now in the “accelerate growth” phase of its strategic roadmap, with global biosimilar launches set to help the firm achieve its goals.

After Dasatinib Apotex Debuts US Tasigna Competition

 
• By 

Canada’s Apotex is continuing to spearhead generic competition in the tyrosine kinase inhibitor (TKI) space for chronic myelogenous leukemia, with the launch of the first generic version of Novartis’ Tasigna (nilotinib) blockbuster.

Abiogen And mAbxience Join Forces In Italy

 
• By 

Spanish biosimilars developer mAbxience has struck a deal with Italy’s Abiogen covering an undisclosed biosimilar for the Italian market.

Krka Looks To Kick On In India And China

 
• By 

Krka has provided updates for its pair of joint ventures in two key Asian markets, India and China, as the Slovenian firm reported its first-quarter financial results.

More from Business

Krka Looks To Kick On In India And China

 
• By 

Krka has provided updates for its pair of joint ventures in two key Asian markets, India and China, as the Slovenian firm reported its first-quarter financial results.

Teva Brings In European Trastuzumab With Prestige BioPharma Agreement

 
• By 

Teva will now market biosimilar Herceptin in both the US and Europe, after penning an agreement with Singaporean firm Prestige BioPharma for its Tuznue rival to the monoclonal antibody to treat HER2-positive breast cancer and HER2-positive metastatic stomach cancer.

SteinCares Deal Leads Lupin’s Ranibizumab Into Latin America

 
• By 

Lupin is planning to make inroads into the Latin American biosimilars market through a deal with local player SteinCares for a ranibizumab rival to Lucentis.